Dulaglutide DUL
GLP-1R agonist (Fc fusion)
GLP-1 receptor agonist of GLP-1 analogue units fused to an Fc fragment, studied for insulin secretion and glycaemic control.
Evidence level. Published human clinical data exists, from trials or approved use. About the badges
- Class
- GLP-1R agonist (Fc fusion)
- Category
- Metabolic & Incretin
- Type
- Single compound
- Abbreviation
- DUL
- Development and regulatory status
- Approved prescription drug (type 2 diabetes, cardiovascular risk reduction)
What researchers study
Dulaglutide is a GLP-1 receptor agonist made of GLP-1 analogue units fused to an immunoglobulin Fc fragment, which extends its time in circulation. It is studied for GLP-1 receptor signalling, insulin secretion and glycaemic control.
Research areas
- Long-acting GLP-1 receptor signalling studies
- Fc-fusion peptide pharmacokinetics
- Insulin secretion and glycaemic control in models
- Cardiovascular outcome research
Reported findings
Summaries of published results. Each one is tagged with the type of study behind it. They describe research outcomes and are not claims about any product. Why study type matters.
- phase 3 trial
In REWIND (9,901 adults with type 2 diabetes, median 5.4 years), the hazard ratio for major cardiovascular events was 0.88 versus placebo
- phase 3 trial
In AWARD-1, mean HbA1c fell by 1.3% to 1.5% across dulaglutide groups at 26 weeks versus 1.0% with exenatide and 0.5% with placebo
Studied alongside
Compounds that appear together in research because their mechanisms complement each other, or as comparators. The reasons given are research reasoning, not recommendations for use.
- Cagrilintideamylin pathway complementary to GLP-1 receptor signalling
- Semaglutidesame-class GLP-1 agonist for comparative receptor studies
- Liraglutideshorter-acting GLP-1 agonist used in comparative pharmacology
